{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:55:28Z","timestamp":1791971728031,"version":"4.3.4"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T00:00:00Z","timestamp":1791936000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sig Transduct Target Ther"],"DOI":"10.1038\/s41392-026-02886-z","type":"journal-article","created":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:37:11Z","timestamp":1791970631000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Targeting an IL-17\/IL-36 pathogenic hub in hidradenitis suppurativa with a bispecific antibody"],"prefix":"10.1038","volume":"11","author":[{"given":"Yonghu","family":"Sun","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zihao","family":"Mi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueqian","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5927-2471","authenticated-orcid":false,"given":"Zhenzhen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lele","family":"Sun","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3521-7130","authenticated-orcid":false,"given":"Baoqi","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuhuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yilei","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kexin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaochen","family":"Ren","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Luan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guowei","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jian","family":"Shi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yongxia","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Minkuo","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mingkai","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peng","family":"Qu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianfeng","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenwen","family":"Sai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yue","family":"Xin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Qingqing","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weizhi","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Na","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hongqing","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuehui","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guoyuan","family":"Peng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xuan","family":"Guo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Guangliang","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiuqiang","family":"Ma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benke","family":"Li","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoxiao","family":"Yan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jianwen","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiabao","family":"You","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gongqi","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chuan","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaopei","family":"Cui","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Zhan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangyang","family":"Zhu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hong","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Furen","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,10,14]]},"reference":[{"key":"2886_CR1","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1016\/S0140-6736(24)02475-9","volume":"405","author":"R Sabat","year":"2025","unstructured":"Sabat, R. et al. Hidradenitis suppurativa. Lancet 405, 420\u2013438 (2025).","journal-title":"Lancet"},{"key":"2886_CR2","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1007\/s13555-018-0264-z","volume":"8","author":"AB Kimball","year":"2018","unstructured":"Kimball, A. B. et al. The comorbidity burden of hidradenitis suppurativa in the United States: a claims data analysis. Dermatol. Ther. 8, 557\u2013569 (2018).","journal-title":"Dermatol. Ther."},{"key":"2886_CR3","doi-asserted-by":"publisher","first-page":"1045","DOI":"10.1016\/j.jaad.2019.08.090","volume":"82","author":"SR Goldburg","year":"2020","unstructured":"Goldburg, S. R., Strober, B. E. & Payette, M. J. Hidradenitis suppurativa: epidemiology, clinical presentation, and pathogenesis. J. Am. Acad. Dermatol. 82, 1045\u20131058 (2020).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2886_CR4","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1016\/j.immuni.2024.04.022","volume":"57","author":"I Subudhi","year":"2024","unstructured":"Subudhi, I. et al. Metabolic coordination between skin epithelium and type 17 immunity sustains chronic skin inflammation. Immunity 57, 1665\u20131680.e7 (2024).","journal-title":"Immunity"},{"key":"2886_CR5","doi-asserted-by":"publisher","first-page":"422","DOI":"10.1056\/NEJMoa1504370","volume":"375","author":"AB Kimball","year":"2016","unstructured":"Kimball, A. B. et al. Two phase 3 trials of adalimumab for hidradenitis suppurativa. N. Engl. J. Med. 375, 422\u2013434 (2016).","journal-title":"N. Engl. J. Med."},{"key":"2886_CR6","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/S0140-6736(23)00022-3","volume":"401","author":"AB Kimball","year":"2023","unstructured":"Kimball, A. B. et al. Secukinumab in moderate-to-severe hidradenitis suppurativa (SUNSHINE and SUNRISE): week 16 and week 52 results of two identical, multicentre, randomised, placebo-controlled, double-blind phase 3 trials. Lancet 401, 747\u2013761 (2023).","journal-title":"Lancet"},{"key":"2886_CR7","doi-asserted-by":"publisher","first-page":"2504","DOI":"10.1016\/S0140-6736(24)00101-6","volume":"403","author":"AB Kimball","year":"2024","unstructured":"Kimball, A. B. et al. Efficacy and safety of bimekizumab in patients with moderate-to-severe hidradenitis suppurativa (BE HEARD I and BE HEARD II): two 48-week, randomised, double-blind, placebo-controlled, multicentre phase 3 trials. Lancet 403, 2504\u20132519 (2024).","journal-title":"Lancet"},{"key":"2886_CR8","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/s41572-020-0149-1","volume":"6","author":"R Sabat","year":"2020","unstructured":"Sabat, R. et al. Hidradenitis suppurativa. Nat. Rev. Dis. Prim. 6, 18 (2020).","journal-title":"Nat. Rev. Dis. Prim."},{"key":"2886_CR9","doi-asserted-by":"publisher","first-page":"508","DOI":"10.1093\/bjd\/ljae144","volume":"191","author":"A Alavi","year":"2024","unstructured":"Alavi, A. et al. Proof-of-concept study exploring the effect of spesolimab in patients with moderate-to-severe hidradenitis suppurativa: a randomized double-blind placebo-controlled clinical trial. Br. J. Dermatol. 191, 508\u2013518 (2024).","journal-title":"Br. J. Dermatol."},{"key":"2886_CR10","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1016\/j.jaad.2024.12.046","volume":"92","author":"LS Ackerman","year":"2025","unstructured":"Ackerman, L. S. et al. Improvements in moderate-to-severe hidradenitis suppurativa with upadacitinib: results from a phase 2, randomized, placebo-controlled study. J. Am. Acad. Dermatol. 92, 1252\u20131260 (2025).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2886_CR11","doi-asserted-by":"publisher","first-page":"521","DOI":"10.1016\/j.jaad.2023.10.034","volume":"90","author":"JS Kirby","year":"2024","unstructured":"Kirby, J. S. et al. Efficacy and safety of the oral Janus kinase 1 inhibitor povorcitinib (INCB054707) in patients with hidradenitis suppurativa in a phase 2, randomized, double-blind, dose-ranging, placebo-controlled study. J. Am. Acad. Dermatol. 90, 521\u2013529 (2024).","journal-title":"J. Am. Acad. Dermatol."},{"key":"2886_CR12","doi-asserted-by":"publisher","first-page":"2213","DOI":"10.1016\/j.jaci.2020.12.651","volume":"147","author":"K Navrazhina","year":"2021","unstructured":"Navrazhina, K. et al. Epithelialized tunnels are a source of inflammation in hidradenitis suppurativa. J. Allergy Clin. Immunol. 147, 2213\u20132224 (2021).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2886_CR13","doi-asserted-by":"publisher","first-page":"e169225","DOI":"10.1172\/JCI169225","volume":"134","author":"KR van Straalen","year":"2024","unstructured":"van Straalen, K. R. et al. Single-cell sequencing reveals Hippo signaling as a driver of fibrosis in hidradenitis suppurativa. J. Clin. Invest. 134, e169225 (2024).","journal-title":"J. Clin. Invest."},{"key":"2886_CR14","doi-asserted-by":"publisher","first-page":"e139930","DOI":"10.1172\/jci.insight.139930","volume":"5","author":"JE Gudjonsson","year":"2020","unstructured":"Gudjonsson, J. E. et al. Contribution of plasma cells and B cells to hidradenitis suppurativa pathogenesis. JCI Insight 5, e139930 (2020).","journal-title":"JCI Insight"},{"key":"2886_CR15","doi-asserted-by":"publisher","first-page":"2827","DOI":"10.1016\/j.immuni.2024.11.010","volume":"57","author":"W-W Yu","year":"2024","unstructured":"Yu, W.-W. et al. Skin immune-mesenchymal interplay within tertiary lymphoid structures promotes autoimmune pathogenesis in hidradenitis suppurativa. Immunity 57, 2827\u20132842.e12 (2024).","journal-title":"Immunity"},{"key":"2886_CR16","doi-asserted-by":"publisher","first-page":"1371","DOI":"10.1016\/j.jid.2024.09.021","volume":"145","author":"J Li","year":"2025","unstructured":"Li, J. et al. Apocrine gland damage and the release of specific keratins in early stage indicate the crucial involvement of apocrine glands in hidradenitis suppurativa. J. Invest. Dermatol. 145, 1371\u20131384.e7 (2025).","journal-title":"J. Invest. Dermatol."},{"key":"2886_CR17","doi-asserted-by":"publisher","first-page":"e70200","DOI":"10.1111\/exd.70200","volume":"35","author":"X Lai","year":"2026","unstructured":"Lai, X. et al. The roles of keratinocytes in the initiation, progression and maintenance of hidradenitis suppurativa. Exp. Dermatol. 35, e70200 (2026).","journal-title":"Exp. Dermatol."},{"key":"2886_CR18","doi-asserted-by":"publisher","first-page":"660","DOI":"10.1093\/bjd\/ljae442","volume":"192","author":"J Rastrick","year":"2025","unstructured":"Rastrick, J. et al. The roles of interleukin (IL)-17A and IL-17F in hidradenitis suppurativa pathogenesis: evidence from human in vitro preclinical experiments and clinical samples. Br. J. Dermatol. 192, 660\u2013671 (2025).","journal-title":"Br. J. Dermatol."},{"key":"2886_CR19","doi-asserted-by":"publisher","first-page":"1434127","DOI":"10.3389\/fimmu.2024.1434127","volume":"15","author":"X Ma","year":"2024","unstructured":"Ma, X. et al. Dual blockade of IL-17A and IL-36 pathways via a bispecific antibody exhibits enhanced anti-inflammatory potency. Front. Immunol. 15, 1434127 (2024).","journal-title":"Front. Immunol."},{"key":"2886_CR20","doi-asserted-by":"publisher","first-page":"2091","DOI":"10.1111\/jdv.14389","volume":"31","author":"R Thomi","year":"2017","unstructured":"Thomi, R. et al. Increased expression of the interleukin-36 cytokines in lesions of hidradenitis suppurativa. J. Eur. Acad. Dermatol. Venereol. 31, 2091\u20132096 (2017).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2886_CR21","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1007\/s00403-019-02012-w","volume":"312","author":"Y Hayran","year":"2020","unstructured":"Hayran, Y. et al. Serum IL-36\u03b1, IL-36\u03b2, and IL-36\u03b3 levels in patients with hidradenitis suppurativa: association with disease characteristics, smoking, obesity, and metabolic syndrome. Arch. Dermatol. Res. 312, 187\u2013196 (2020).","journal-title":"Arch. Dermatol. Res."},{"key":"2886_CR22","doi-asserted-by":"publisher","first-page":"886","DOI":"10.1111\/exd.13978","volume":"28","author":"JW Frew","year":"2019","unstructured":"Frew, J. W. et al. Contribution of fibroblasts to tunnel formation and inflammation in hidradenitis suppurativa\/acne inversa. Exp. Dermatol. 28, 886\u2013891 (2019).","journal-title":"Exp. Dermatol."},{"key":"2886_CR23","doi-asserted-by":"publisher","first-page":"1004","DOI":"10.1111\/bjd.19538","volume":"184","author":"S Narla","year":"2021","unstructured":"Narla, S. et al. Identifying key components and therapeutic targets of the immune system in hidradenitis suppurativa with an emphasis on neutrophils. Br. J. Dermatol. 184, 1004\u20131013 (2021).","journal-title":"Br. J. Dermatol."},{"key":"2886_CR24","doi-asserted-by":"publisher","first-page":"1015","DOI":"10.1016\/j.jaci.2022.10.034","volume":"151","author":"R Sabat","year":"2023","unstructured":"Sabat, R. et al. Neutrophilic granulocyte-derived B-cell activating factor supports B cells in skin lesions in hidradenitis suppurativa. J. Allergy Clin. Immunol. 151, 1015\u20131026 (2023).","journal-title":"J. Allergy Clin. Immunol."},{"key":"2886_CR25","doi-asserted-by":"publisher","first-page":"i3","DOI":"10.1093\/bjd\/ljae238","volume":"192","author":"JW Frew","year":"2025","unstructured":"Frew, J. W. Unravelling the complex pathogenesis of hidradenitis suppurativa. Br. J. Dermatol. 192, i3\u2013i14 (2025).","journal-title":"Br. J. Dermatol."},{"key":"2886_CR26","first-page":"581","volume":"19","author":"Y Yu","year":"2025","unstructured":"Yu, Y., Li, J., Liu, H., Sun, Y. & Zhang, F. Dual blocking of IL17A and IL36R for the treatment of refractory hidradenitis suppurativa: a case report. Biologics 19, 581\u2013584 (2025).","journal-title":"Biologics"},{"key":"2886_CR27","doi-asserted-by":"publisher","first-page":"1421","DOI":"10.1111\/jdv.20369","volume":"39","author":"CC Zouboulis","year":"2025","unstructured":"Zouboulis, C. C. et al. Secukinumab efficacy in patients with hidradenitis suppurativa assessed by the International Hidradenitis Suppurativa Severity Score System (IHS4): a post hoc analysis of the SUNSHINE and SUNRISE trials. J. Eur. Acad. Dermatol. Venereol. 39, 1421\u20131430 (2025).","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"2886_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/JD9.0000000000000204","volume":"5","author":"ZS Wang","year":"2022","unstructured":"Wang, Z. S. et al. Prevalence of acne inversa (hidradenitis suppurativa) in China: a Nationwide Cross-Sectional Epidemiological Study. Int J. Dermatol Venereol. 5, 1\u20137 (2022).","journal-title":"Int J. Dermatol Venereol."},{"key":"2886_CR29","doi-asserted-by":"publisher","first-page":"1572802","DOI":"10.3389\/fimmu.2025.1572802","volume":"16","author":"W Chen","year":"2025","unstructured":"Chen, W., Zhou, A. & Zhou, Y. Bispecific antibody for lung cancer: mechanisms and clinical insights. Front. Immunol. 16, 1572802 (2025).","journal-title":"Front. Immunol."},{"key":"2886_CR30","doi-asserted-by":"publisher","first-page":"e008037","DOI":"10.1136\/jitc-2023-008037","volume":"12","author":"S Frentzas","year":"2024","unstructured":"Frentzas, S. et al. Phase 1a dose escalation study of ivonescimab (AK112\/SMT112), an anti-PD-1\/VEGF-A bispecific antibody, in patients with advanced solid tumors. J. Immunother. Cancer 12, e008037 (2024).","journal-title":"J. Immunother. Cancer"},{"key":"2886_CR31","doi-asserted-by":"publisher","first-page":"102106","DOI":"10.1016\/j.eclinm.2023.102106","volume":"62","author":"Y Zhao","year":"2023","unstructured":"Zhao, Y. et al. AK112, a novel PD-1\/VEGF bispecific antibody, in combination with chemotherapy in patients with advanced non-small cell lung cancer (NSCLC): an open-label, multicenter, phase II trial. EClinicalMedicine 62, 102106 (2023).","journal-title":"EClinicalMedicine"},{"key":"2886_CR32","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50283-3","volume":"15","author":"T Liu","year":"2024","unstructured":"Liu, T. et al. Single-cell transcriptomics analysis of bullous pemphigoid unveils immune-stromal crosstalk in type 2 inflammatory disease. Nat. Commun. 15, 5949 (2024).","journal-title":"Nat. Commun."},{"key":"2886_CR33","doi-asserted-by":"publisher","first-page":"3573","DOI":"10.1016\/j.cell.2021.04.048","volume":"184","author":"Y Hao","year":"2021","unstructured":"Hao, Y. et al. Integrated analysis of multimodal single-cell data. Cell 184, 3573\u20133587.e29 (2021).","journal-title":"Cell"},{"key":"2886_CR34","doi-asserted-by":"publisher","first-page":"329","DOI":"10.1016\/j.cels.2019.03.003","volume":"8","author":"CS McGinnis","year":"2019","unstructured":"McGinnis, C. S., Murrow, L. M. & Gartner, Z. J. DoubletFinder: doublet detection in single-cell RNA sequencing data using artificial nearest neighbors. Cell Syst. 8, 329\u2013337.e4 (2019).","journal-title":"Cell Syst."},{"key":"2886_CR35","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1186\/s13059-020-1950-6","volume":"21","author":"S Yang","year":"2020","unstructured":"Yang, S. et al. Decontamination of ambient RNA in single-cell RNA-seq with DecontX. Genome Biol. 21, 57\u201371 (2020).","journal-title":"Genome Biol."},{"key":"2886_CR36","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1186\/s13059-019-1850-9","volume":"21","author":"HTN Tran","year":"2020","unstructured":"Tran, H. T. N. et al. A benchmark of batch-effect correction methods for single-cell RNA sequencing data. Genome Biol. 21, 12\u201343 (2020).","journal-title":"Genome Biol."},{"key":"2886_CR37","doi-asserted-by":"publisher","first-page":"180","DOI":"10.1038\/s41596-024-01045-4","volume":"20","author":"S Jin","year":"2025","unstructured":"Jin, S., Plikus, M. V. & Nie, Q. CellChat for systematic analysis of cell\u2013cell communication from single-cell transcriptomics. Nat. Protoc. 20, 180\u2013219 (2025).","journal-title":"Nat. Protoc."},{"key":"2886_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1038\/s41587-021-01033-z","volume":"40","author":"E Dann","year":"2022","unstructured":"Dann, E., Henderson, N. C., Teichmann, S. A., Morgan, M. D. & Marioni, J. C. Differential abundance testing on single-cell data using k-nearest neighbor graphs. Nat. Biotechnol. 40, 245\u2013253 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2886_CR39","doi-asserted-by":"publisher","first-page":"268","DOI":"10.1038\/s41586-018-0694-x","volume":"564","author":"L Zhang","year":"2018","unstructured":"Zhang, L. et al. Lineage tracking reveals dynamic relationships of T cells in colorectal cancer. Nature 564, 268\u2013272 (2018).","journal-title":"Nature"},{"key":"2886_CR40","doi-asserted-by":"publisher","first-page":"517","DOI":"10.1038\/s41587-021-00830-w","volume":"40","author":"DM Cable","year":"2022","unstructured":"Cable, D. M. et al. Robust decomposition of cell type mixtures in spatial transcriptomics. Nat. Biotechnol. 40, 517\u2013526 (2022).","journal-title":"Nat. Biotechnol."},{"key":"2886_CR41","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-50481-z","volume":"15","author":"P Shi","year":"2024","unstructured":"Shi, P. et al. Loss-of-function mutations in Keratin 32 gene disrupt skin immune homeostasis in pityriasis rubra pilaris. Nat. Commun. 15, 6259 (2024).","journal-title":"Nat. Commun."},{"key":"2886_CR42","doi-asserted-by":"publisher","first-page":"566607","DOI":"10.3389\/fimmu.2020.566607","volume":"11","author":"P Henrot","year":"2020","unstructured":"Henrot, P. et al. A method for isolating and culturing skin cells: application to endothelial cells, fibroblasts, keratinocytes, and melanocytes from punch biopsies in systemic sclerosis skin. Front. Immunol. 11, 566607 (2020).","journal-title":"Front. Immunol."},{"key":"2886_CR43","unstructured":"CNCB-NGDC Members and Partners. Database Resources of the National Genomics Data Center, China National Center for Bioinformation in 2025. Nucleic Acids Res. 53, D30\u2013D44 (2024)."},{"key":"2886_CR44","doi-asserted-by":"publisher","first-page":"qzaf072","DOI":"10.1093\/gpbjnl\/qzaf072","volume":"23","author":"S Zhang","year":"2025","unstructured":"Zhang, S. et al. The GSA family in 2025: a broadened sharing platform for multi-omics and multimodal data. Genomics Proteom. Bioinforma. 23, qzaf072 (2025).","journal-title":"Genomics Proteom. Bioinforma."}],"container-title":["Signal Transduction and Targeted Therapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02886-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02886-z","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02886-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,10,14]],"date-time":"2026-10-14T09:37:14Z","timestamp":1791970634000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41392-026-02886-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,10,14]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["2886"],"URL":"https:\/\/doi.org\/10.1038\/s41392-026-02886-z","relation":{},"ISSN":["2059-3635"],"issn-type":[{"value":"2059-3635","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,10,14]]},"assertion":[{"value":"25 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"7 June 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"16 June 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 October 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests.","order":1,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Ethics"}}],"article-number":"445"}}